FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
-
-
35 | Real-world outcomes of targeted therapy in stage IV melanoma after relapse on adjuvant dabrafenib and trametinib: insights from a single-center cohort Rossella Villani, Chiara Bungaro, Anna Cecere, Ileana De Roma, Sabino Strippoli, Michele Guida | Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
336 -
22 | Surgical radicality and reconstructive techniques in melanoma and non-melanoma skin cancer A. Lenta, A. Amore, L. Benedetto, C. Caracò | Chirurgia del Melanoma e dei tumori cutanei, Istituto Nazionale Tumori "Fondazione Pascale", Napoli, Italy.
305 -
27 | Real-world data for malignant melanoma stage II adjuvant therapy Silvana Cozzolino1, Antonino Colloca1, Miriam Forte1, Francesco Caraglia1, Alfonso Esposito1, Maria Cristina Giugliano1, Eleonora Cioli1, Marcella Scala2, Maria Chiara Sergi3, Teresa Del Giudice4, Francesca Sparano5, Immacolata Paciolla6, Mariangela Pasqualoni7, Luigi Formisano2, Stefania Napolitano1, Antonio Maria Grimaldi1, Paolo Antonio Ascierto5, Fortunato Ciardiello1, Teresa Troiani1, Vincenzo De Falco1 | 1Medical Oncology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples; 2Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; 3Division of Medical Oncology, "Mons. A.R. Dimiccoli" Hospital, Barletta; 4Nuclear Medicine Unit, "Mater Domini" University Hospital, Catanzaro; 5Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples; 6Medical Oncology Unit, AORN "San Pio", Benevento, Italy; 7Medical Oncology Unit, ASL Taranto, Italy.
326 -
New and emerging therapies in cutaneous T-cell lymphoma
1062PDF: 579HTML: 93 -
32 | Tebentafusp in metastatic uveal melanoma: 3 years of real world data and insights from liquid biopsy Luisa Piccin1, Maria Chiara Scaini2, Valentina Salizzato1, Cristina Catoni2, Elisabetta Di Liso1, Alice Menichetti1, Chiara Cacco1|4, Chiara Gottardi1|4, Francesca Di Sarra3, Marina Coppola3, Valentina Guarneri1|4, Jacopo Pigozzo1 | 1Medical Oncology 2 - Veneto Institute of Oncology IOV-IRCCS; 2Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS; 3Pharmacy Unit - Veneto Institute of Oncology IOV-IRCCS; 4Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
258 -
19 | Late draining lymph nodes on preoperative lymphoscintigraphy in melanoma patients: preliminary data from a retrospective study of over 400 cases Tiziano Pallara, Giovanni Marruzzo, Emilia Migliano | UOSD Chirugia Plastica ad Indirizzo Dermatologico e Rigenerativo, IRCCS IFO Istituto San Gallicano, Roma, Italy.
271 -
03 | Pancreatic cancer burden in Italian CDKN2a-positive families followed for up to 25 years Eleonora Allavena1|2, Bruna Dalmasso2, Andrea Gambino2, Francesca Barbero2, Irene Vanni2, Cansu Gorgun1, Francesco Spagnolo2|4, Enrica Tanda3, Andrea Boutros3, William Bruno1|2, Lorenza Pastorino1|2, Paola Ghiorzo1|2 | 1Department of Internal Medicine and Medical Specialties - DiMI, University of Genoa; 2Cancer Genetics Unit, IRCCS Ospedale Policlinico San Martino, Genoa; 3Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa; 4Department of Surgical and Diagnostic Integrated Sciences, University of Genoa, Genoa, Italy.
343 -
25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo1|2, Carlo Resteghini1|2, Sara Farinatti1|2, Andrea Alberti3, Valeria Tovazzi3, Paola Queirolo4, Maristella Saponara4, Giuseppe Argenziano5, Riccardo Marconcini6, Ketty Peris7, Paola Savoia8, Maria Chiara Tronconi1, Iris Zalaudek9, Paolo Ascierto10, Francesco Spagnolo11, Luigi Lorini1, Cristina Gurizzan1, Paolo Bossi1|2 | 1Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano MI; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; 3Medical Oncology Unit, ASST Spedali Civili, Brescia; 4Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; 5Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; 6Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; 7Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; 8Department of Health Sciences, University of Eastern Piedmont, Novara; 9Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; 10Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; 11Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
302 -
11 | Challenges in developing a digital pathology consultation network: insights from the MELCAYA experience Filippo Ugolini1, Dario Di Gangi2, Roberta Gugliotta3, Anna Szumera-Ciećkiewicz4|5, Llucia Alos6, Natalia Castrejón6, Stephan Forchhammer7, Barbara Valeri8, Nicolas Macagno9, Sule Ozturk Sari10, Ozge Hurdogan10, Sokol Sina11, Sylvie Fraitag12, Valerio Gaetano Vellone13, Chiara Trambaiolo13, Rita Alaggio14, Sabrina Rossi14, Giovanni Arcuri3, Daniela Massi2, Claudio Conti3 | 1Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy. 2Section of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy. 3UOC Direzione Tecnica, ICT ed Innovazione Tecnologie Sanitarie, Fondazione Policlinico Agostino Gemelli IRCCS, Roma, Italy. 4Biobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 5Department of Pathology , Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 6Department of Pathology, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.7Department of Dermatology, University Medical Center, Eberhard Karls University Tübingen, Tübingen, Germany. 8Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 9Aix-Marseille University, Marmara Institute, INSERM, U1251, MMG, DOD-CET, Marseille, France. 10Department of Pathology, Istanbul University Istanbul Medical Faculty, Istanbul, Türkiye; 11Section of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 12Pathology Department, Necker-Enfants Malades Hospital, AP-HP, Paris, France; 13Pathology Unit, IRCCS Istituto Giannina Gaslini, Genoa; 14Pathology Unit, Department of Laboratories, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
351 -
The top 100 most cited articles in acne vulgaris: a bibliometric analysis
3118PDF: 577SUPPLEMENTARY MATERIAL: 168HTML: 15 -
Dermatology Reports: a journal coming to a new life
753PDF: 372HTML: 8 -
17 | The role of sentinel lymph node biopsy in pt1a, pt1b and pt2a melanomas: a 10-year experience through 2025 Gabriele Roccuzzo1, Nicolas Destefanis2, Giulia Orlando3, Eleonora Bergamo1, Virginia Caliendo4, Adriana Lesca5, Daniela Zugna2, Franco Picciotto4, Rebecca Senetta3, Simone Ribero1, Pietro Quaglino1 | 1Department of Medical Sciences, Section of Dermatology, University of Turin; 2Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin; 3Department of Oncology, Section of Surgical Pathology, University of Turin; 4Dermatologic Surgery Section, Department of Surgery, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Turin; 5Division of Nuclear Medicine, Department of Medical Science, University of Turin, Italy.
297
